About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 30 Apr 2020 Results for Fourth Period and Eleven Months Ended December 31, 2019 Press Releases / 14 Apr 2020 Summit Appoints Robert W. Duggan as Chief Executive Officer Press Releases / 26 Feb 2020 Summit Appoints Robert W. Duggan as Executive Chairman Press Releases / 06 Feb 2020 Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Press Releases / 23 Jan 2020 Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Press Releases / 07 Jan 2020 Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Press Releases / 17 Dec 2019 Financial Results for the Third Quarter Ended 31 October 2019 Press Releases / 17 Dec 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Press Releases / 06 Dec 2019 Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting Press Releases / 06 Nov 2019 Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress Press Releases / 04 Nov 2019 Summit Therapeutics Recognises C. difficile Awareness Month Press Releases / 16 Oct 2019 Summit Therapeutics to Present at the 2019 BIO Investor Forum << 1 2 3 … 27 28 >>
Press Releases / 30 Apr 2020 Results for Fourth Period and Eleven Months Ended December 31, 2019 Press Releases / 14 Apr 2020 Summit Appoints Robert W. Duggan as Chief Executive Officer Press Releases / 26 Feb 2020 Summit Appoints Robert W. Duggan as Executive Chairman Press Releases / 06 Feb 2020 Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Press Releases / 23 Jan 2020 Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Press Releases / 07 Jan 2020 Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Press Releases / 17 Dec 2019 Financial Results for the Third Quarter Ended 31 October 2019 Press Releases / 17 Dec 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Press Releases / 06 Dec 2019 Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting Press Releases / 06 Nov 2019 Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress Press Releases / 04 Nov 2019 Summit Therapeutics Recognises C. difficile Awareness Month Press Releases / 16 Oct 2019 Summit Therapeutics to Present at the 2019 BIO Investor Forum
Press Releases / 06 Feb 2020 Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
Press Releases / 23 Jan 2020 Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
Press Releases / 07 Jan 2020 Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
Press Releases / 17 Dec 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
Press Releases / 06 Dec 2019 Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
Press Releases / 06 Nov 2019 Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
